Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

A Phase II Trial of Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04149015
• Other study ID #: FNF015
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: November 2019
• Est. completion date: December 31, 2023

Study information

• Verified date: October 2019
• Source: Fujian Cancer Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single center, phase II study, to evaluate the effectiveness and safety of POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the neoadjuvant therapy for patients with advanced/metastatic gastric cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• 18-75 years old;

• Patients must have histologically or cytologically confirmed resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma without distant metastases. GEJ adenocarcinoma may be classified according to Siewert's classification type I, II, or III

• Patients may have received no prior chemotherapy.

• Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1;

• An expected survival of = 3 months;

• Major organ function has to meet the following criteria; (1) For results of blood routine test:

• Hemoglobin (HB) = 80g / L,

• ANC(absolute neutrophil count) = 1.5 × 109 / L,

• PLT(blood platelet) = 75 × 109 / L, (2) For results of biochemical tests:

• BLT(total bilirubin) = 1.25 times the upper limit of normal (ULN),

• ALT(Alanine aminotransferase) and AST(aspartate aminotransferase ) = 2.5 × ·ULN, liver metastases, if any, the ALT and AST= 5 × ULN,

• Serum Cr(creatinine)=1ULN, Endogenous creatinine clearance rate >50ml/min;

• The patient has a PT(prothrombintime) (INR international normalized ratio) < or = to 1.5 and an PTT(Partial Thromboplastin Time)< than or = to 3 seconds above the upper limits of normal if the patientia t is not on anticoagulation. ·If a patient is on full-dose anticoagulants, the following criteria should be met for enrollment:

• The patient must have an in-range INR (usually between 2 and 3) on a stable dose of warfarin or on stable dose of LMW(Low molecular weight) heparin

• The patient must not have active bleeding or pathological conditions that carry high risk of bleeding (e.g. tumor involving major vessels, known varices)

• Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative.

• Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.

• Ability to understand informed consent and signing of written informed consent document prior to initiation of protocol therapy.

Exclusion Criteria:

1. Subjects with second primary cancer, besides dermatoma, primary cancer of nervous system, non-metastatic prostatic neoplasms.

2. Gastrointestinal bleeding.

3. women of child-bearing age must take a negative result of serum pregnancy test within 7 days prior to enrollment, and willing to use appropriate methods of contraception during the trial and 12 weeks after the last trial drug. For men, who willing to use appropriate methods of contraception during the trial and 12 weeks after the last trial drug.

4. Ongoing corticosteroid drug therapy.

5. With a history of previous severe cardiovascular disease: over grade-two myocardial ischemia or myocardial infarction, congestive hert filure, and myocardial infarction or coagulopathy within 6 months.

6. Having got apoplexy or cardiovascular accident within 6 months.

7. Having got severe peripheral vascular disease in clinics.

8. Subjects who have a history of psychiatric substance abuse and cannot quit or have mental disorders.

9. The researchers concluded that the subjects were not suitable for clinic trial

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• paclitaxel ,oxaliplatin,fluorouracil
A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Fujian Cancer Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological complete and subtotal regression (TRG1a/b by Becker)	Pathological complete and subtotal regression (TRG1a/b by Becker). TRG1a/b is defined as < 10% residual tumor per tumor bed based on evaluation of the resected esophagogastric specimen in the primary by a pathologist.	after 4 cycles (each cycle is 14 days) + surgery; i.e. after 12 weeks in total